– USA, MA – Generate:Biomedicines announced the appointment of Dr. Rupert Vessey (M.D., Ph.D.) and Dr. Nancy Simonian (M.D.) to its Board of Directors.
““As Generate begins to see early clinical data and expand the applications of its generative AI platform, the combined expertise of Rupert and Nancy will be a significant asset. On behalf of the Board, we look forward to working with them to realize the full potential of Generate’s transformative and pioneering approach to drug discovery and development,” said Co-Founder and Chairman Dr. Noubar Afeyan.
Dr. Vessey’s expertise in early-stage drug discovery and evolving bioplatforms, combined with Dr. Simonian’s success in clinical development and bringing therapies to patients, will further the company’s mission to revolutionize drug discovery and development.
About Dr. Rupert Vessey
Dr. Vessey brings a wealth of experience in the early stages of drug discovery. He served as Executive Vice President and President of research at Bristol-Myers Squibb and has held senior leadership roles at Celgene, Merck, and GlaxoSmithKline, overseeing numerous programs from initial discovery through proof-of-concept. Dr. Vessey’s strategic insights and hands-on experience with bioplatforms, particularly in his role at Flagship Pioneering as Chief Scientist and Executive Partner, will be instrumental in advancing The Generate Platform and the company’s early-stage programs.
About Dr. Nancy Simonian
Dr. Simonian is a recognized leader in clinical development, with a proven track record of successfully bringing new therapies to patients. As the founding CEO of Syros Pharmaceuticals, she transformed the company from a startup into a publicly traded late clinical-stage company. Dr. Simonian has overseen the development of groundbreaking therapies such as AVONEX, TYSABRI, VELCADE, and ENTYVIO during her time at Biogen and Millennium Pharmaceuticals, making a significant impact on patient care. Her experience and leadership in company building and advancing clinical programs will greatly enhance the company’s efforts to deliver next-generation therapeutics.
About Generate:Biomedicines
Generate:Biomedicines is the first drug generation company pioneering a machine learning-powered generative biology platform with the ability to create new drugs on demand across a wide range of biologic modalities. The Generate Platform – a continuous loop to generate, build, measure, and learn – can drastically increase the speed at which targets and therapeutics are identified and validated. This innovation improves the specificity of target engagement by generating proteins and reduces the time and cost of developing clinical candidates. Founded by Flagship Pioneering in 2020 after two years of foundational research, Generate is a clinical-stage company dedicated to revolutionizing drug discovery and development.
For more: https://www.generatebiomedicines.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.